DxS' TheraScreen Gets Canadian OK

Health Canada granted a marketing license for DxS' TheraScreen: K-RAS Mutation Kit as a companion diagnostic for Amgen's colorectal cancer therapy panitumumab (Vectibix).

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.